Download Free Medical Overview of Female Sexual Dysfunction for the Primary Care Physician PowerPoint Presentation

Overview of Female Sexual Dysfunction for the Primary Care Physician PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Female Reproductive System, which is titled "Overview of Female Sexual Dysfunction for the Primary Care Physician", to get an overview of female sexual dysfunction.

Tags : Female Reproductive System, Overview, Female Sexual Dysfunction

Published on : Jul 28, 2021 | Views : 2227 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Overview of Female Sexual Dysfunction for the Primary Care Physician WVU WOMENS HEALTH CURRICULUM – Revisions 9/2008 Stanley Zaslau, MD, MBA, FACS Program Director & Associate Professor Division of Urology West Virginia University
Slide 2-

Objectives - 1 In this lecture, participants will learn: Incidence, epidemiology and pathophysiology of Female Sexual Dysfunction Female pelvic anatomy AFUD Classification of Female Sexual Disorders Clinical Evaluation of the Female Sexual response
Slide 3-

Objectives - 2 In this lecture, participants will learn: Treatment of FSD Oral agents Neutraceuticals Vacuum Clitoral Erection Device Potential novel therapies
Slide 4-

Incidence 30 million men with compromised erectile function Paucity of epidemiologic data regarding incidence of female sexual dysfunction multi-causal multi-dimensional age-related progressive highly prevalent
Slide 5-

Incidence National Health and Social Life Survey (1999) 1749 Women 33% of women lack sexual interest 25% of women do not experience orgasm 20% of women report lubrication difficulties 20% of women report sex is not pleasurable Laumann E, Paik A, Rosen R. Sexual dysfunction in the United States: Prevalence and predictors, JAMA 1999;281;537-544.
Slide 6-

Incidence Sexuality in Older Women (Diokno, 1990 and Mooradian 1990) 448 women over the age of 60 66% are sexually inactive 12% of married women had difficulty with intercourse; 14% experienced dyspareunia Sexuality positively correlated with marital status Less likely to have sex if partners in poor health Diokno AC, et al. Sexual function in the elderly. Archives of Internal Medicine 1990;150:197-200.
Slide 7-

Incidence Rosen (1993) Study 329 women age 18 to 73 years Most common areas of dysfunction 38% lack of desire 16% lack of pleasure Age and relationship status predict FSD single and older women highest incidence Rosen (1993) Journal of Sexual and Marital Therapy
Slide 8-

Female Pelvic Anatomy Vagina Vascular supply, innervation and physiologic changes Clitoris Vascular supply, innervation and physiologic changes Vestibular bulbs Uterus Pelvic Floor Muscles
Slide 9-

Vagina-Anatomy & Blood Supply Labia minora surrounds vagina; protected by outer labia majora Labia minora enclose the vestibule which contains: Clitoris Vaginal opening -- Urethral opening Innervation Autonomic Somatic motor fibers of S2-S4 innervate bulbocavernosis and ischiocavernosus muscles Pudendal nerve—sensory to introitus Main arterial supply (extensive anastomosis) Vaginal branches of the uterine arteries Vaginal branches of the pudendal arteries Ovarian arteries
Slide 10-

Clitoris-Anatomy & Blood Supply Erectile organ similar to the penis Blood supply Iliohypogastric-pudendal arterial bed Internal pudendal artery branches to form common clitoral artery --> dorsal and cavernosal clitoral arteries Consists of fused midline corpora cavernosa Unable to trap venous blood With sexual stimulation, engorgement, rather than erection occurs
Slide 11-

Vestibular Bulbs Paired, 3-cm structures along the vaginal orifice Homologous to corpus spongiosum of the penis Composed of vascular smooth muscle Arterial supply: branches of internal pudendal artery Sensory innervation: posterior branches of the pudendal nerve
Slide 12-

Uterus Uterine/cervical glands secrete mucus during sexual arousal Uterine/pelvic procedures interrupt vaginal innervation --> negative impact on later sexual health Disruption of uterosacral and cardinal ligaments can result in genital arousal and orgasm difficulties Role for nerve sparing procedures as similar to those performed in men
Slide 13-

Pelvic Floor Muscles Pelvic diaphragm formed by: Levator ani muscles Urogenital diaphragm Peroneal membrane, composed of ischiocavernosus, bulbocavernosus and superficial transverse perinii muscles Muscles pull rectum, vagina and urethra anteriorly towards pubic bone
Slide 14-

Pelvic Floor Muscles Non-voluntary spasm of pelvic floor=vaginismus Laxity or hypotonia of pelvic floor, associated with vaginal hypoanesthesia anorgasmia incontinence Question all women with voiding dysfunction about their sexual function!!
Slide 15-

Female Sexual Physiology: Normal Physiological changes during arousal Enlargement of clitoris Dilation of arterioles, increased vaginal and clitoral blood flow Seeping of vascular transudate across vaginal membrane ---> lubrication Expansion and tenting of upper 1/2 of vagina Response mediated by nitric oxide (role for sildenafil)
Slide 16-

AFUD Classification and Definition of Female Sexual Disorders Consensus classification (AFUD Consensus Panel, 1998) Hypoactive Sexual Desire Disorder Sexual Aversion Disorder Orgasmic disorders Sexual pain disorders Dyspareunia Vaginismus Other sexual pain disorders
Slide 17-

Hypoactive Sexual Desire Disorder Hypoactive sexual desire disorder Persistent or recurrent deficiency (or absence) of sexual fantasies/thoughts or desire for a receptivity to sexual activity Causes personal distress Differential diagnosis: surgical or medical menopause endocrine disorders
Slide 18-

Sexual Aversion Disorder Sexual Aversion Disorder Persistent or recurrent phobic aversion to and avoidance of sexual contact with a sexual partner Causes personal distress Results from: childhood trauma (physical or sexual abuse)
Slide 19-

Sexual Arousal Disorder Persistent or recurrent inability to attain or maintain sufficient sexual excitement Causes personal distress Differential diagnosis: medical causes, prior pelvic trauma, pelvic surgery, medications May be expressed as lack of subjective excitement or lack of genital lubrication/swelling
Slide 20-

Orgasmic Disorder Persistent or recurrent difficulty, delay in or absence of attaining orgasm following sexual stimulation Causes personal distress Primary (never attained orgasm)--emotional trauma or sexual abuse Secondary Surgery Hormone deficiency -- Trauma
Slide 21-

Sexual Pain Disorders Dyspareunia Recurrent or persistent genital pain with sexual intercourse Consider: vestibulitis vaginal atrophy vaginal infection
Slide 22-

Sexual Pain Disorders Vaginismus Recurrent or persistent involuntary spasm of the musculature of the outer third of the vagina that interferes with vaginal penetration. Conditioned response to painful penetration (?psychological or emotional)
Slide 23-

Other Sexual Pain Disorders Herpes Simplex Virus Vestibulitis Prior genital mutilation Trauma Endometriosis Interstitial cystitis
Slide 24-

Interstitial Cystitis (IC) and Female Sexual Dysfunction (FSD) Pain associated with intercourse Entry dyspareunia Deep dyspareunia
Slide 25-

IC and FSD 100 patients with IC FSFI administered Assess 6 domains of sexual function Desire Arousal Orgasm Lubrication Satisfaction Pain Zaslau, et al. WVMJ 2008
Slide 26-

IC and FSD Results: Mean age 39 years Impairment in all domains “50-75% of the time” Conclusions FSD in IC involves more than pelvic pain Zaslau, S et al FSFF, Vancouver, BC 2002
Slide 27-

FSD in IC: 1st 400 Patients 400 IC patients FSFI administered on line at IC-Network Compared to two groups Controls (131) Female sexual arousal disorder (129)
Slide 28-

FSD in IC 1st 400 Patients Results Statistically significant decrease in all domains when compared to controls Stastically significant decrease in all domains when compared to Arousal Disorder Group Lowest scores: pain Zaslau, et al AUA 2003, Chicago, IL.
Slide 29-

Conclusions: IC and FSD Global sexual dysfunction affecting all domains May be age related and progressive Pain domain has lowest scores Treatment is multimodal and may involve counseling, sex therapy and physical therapy
Slide 30-

Etiologies of Female Sexual Dysfunction Vasculogenic Neurogenic Hormonal/Endocrine Musculogenic Psychogenic
Slide 31-

Vasculogenic Risk factors: hypertension, hypercholesterolemia, smoking, heart disease Associated with ED in men and sexual dysfunction in women Diminished vaginal and clitoral blood flow (atherosclerosis) Results in symptoms of vaginal dryness and dyspareunia Alteration of circulating estrogen levels: atrophy of vaginal and clitoral smooth muscle Traumatic arterial disruption: pelvic fracture, blunt trauma, surgical disruption, chronic perineal pressure (bicycle riding)
Slide 32-

Neurogenic Spinal cord injury (SCI) to the central or peripheral nervous system Diabetes mellitus Complete upper motor neuron lesions of the sacral cord Incomplete SCI: capacity for psychogenic arousal and vaginal lubrication
Slide 33-

Hormonal/Endocrine Disorders of the hypothalamic-pituitary axis Medical or surgical castration Premature ovarian failure Chronic birth control use Symptoms: decreased desire, vaginal dryness, lack of sexual arousal
Slide 34-

Musculogenic Lavator ani muscles Perineal membrane bulbocavernosus and ischiocavernosus muscle Contraction contributes to arousal and orgasm Hypertonicity ---> vaginismus or dyspareunia Hypotonicity ---> vaginal hypoanesthesia, coital anorgasmia, urinary incontinence during sexual intercourse or orgasm
Slide 35-

Psychogenic Emotional and relational issues self esteem body image quality of the relationship with the partner Medications serotonin re-uptake inhibitors
Slide 36-

Clinical Evaluation of the Female Sexual Response Medical/Physiologic Evaluations Psychosocial/Psychosexual Assessment
Slide 37-

Medical/Physiologic Evaluations Full history, physical exam, pelvic exam Hormonal profile (FSH, LH, prolactin, free testosterone, SHBG, estradiol) Evaluation of the sexual response Genital blood flow (Duplex doppler ultrasound) Vaginal pH Vaginal compliance/elasticity Genital sensation by vibratory perception threshold
Slide 38-

Psychosocial/Psychosexual Assessment Address emotional and relational issues Subjective assessment of sexual function Brief Index of Sexual Function (BISF-W) Inventory of Female Sexual Function (IFSF)
Slide 39-

Therapy Sildenafil Dehydroepiandesterone (DHEA) Alprostadil (PGE1) Apomorphine L-arginine and Yohimbine Vacuum Clitoral Therapy Device
Slide 40-

Sildenafil and Female Sexual Dysfunction 33 post menopausal women in prospective study Excluded: heart disease, uncontrolled psych disorder, poorly controlled DM, alcohol abuse, CVA, history of MI or concurrent nitrate therapy Took sildenafil 50 mg 1 hour prior to planned sexual activity Given a 9 item Index of Female Sexual Function Questionnaire
Slide 41-

Sildenafil and Female Sexual Dysfunction Results 3 patients dropped out because of adverse effects Clitoral hypersensitivity in 7 (21%) Headache, dyspepsia, dizziness No differences in intercourse satisfaction and sexual desire after 3 months of therapy Women on HRT had an increased overall score (not statistically significant)
Slide 42-

Sildenafil and Female Sexual Dysfunction Comments No placebo arm Raises several questions What is the potential role for other oral agents such as phentolamine and apomorphine? Would higher doses of sildenafil produce a better response? Role for combination therapy? Role for topical therapy?
Slide 43-

Sildenafil in SCI Women with FSD 50% of women achieve orgasm regardless of injury type (complete vs. incomplete) Sildenafil given to 19 women with SCI Results in significant increases in subjective arousal sexual stimulation heart rate and decreases in blood pressure Sipski M, Grand Master Lecture #2, Female Sexual Function Forum, 2000
Slide 44-

Sildenafil for FSD in Women with Depression 50% of patients on SSRI have some sexual dysfunction Study: 10 women with depression on SSRI with FSD 50 mg sildenafil prior to sexual activity Results: 9/10 had reversal of anorgasmia or delayed orgasm; most with 1st dose of sildenafil Hensley et al. Sildenafil for Iatrogenic Seritonergic antidepressant medication induced sexual dysfunction. Female Sexual Function Forum, 2000.
Slide 45-

Sildenafil after Hysterectomy? 35 women evaluated after hysterectomy BISF-Q survey used for pre/post treatment assessment 100 mg sildenafil given for 6 weeks Results: “Improved” sensation “Improved” ability to reach orgasm “Decreased” pain and discomfort Berman, et al. Hysterectomy and Sexual Function: A Role for Sildenafil?, Female Sexual Function Forum, 2000.
Slide 46-

Dehydroepiandosterone (DHEA) Adrenal gland hormone, precursor to sex steroids testosterone and estradiol Given in daily doses of 50, 75 and 100 mg Included women with sexual dysfunction for more than 6 months and low testosterone levels Treatment duration 2 to 6 months Results: Increase in mean and free testosterone levels Improvement in Sexual Distress Scale Scores Suggests: DHEA may be useful for women with FSD and low testosterone Munnariz, et al. Lowered Personal Sexual Distress Scale Scores Following DHEA Treatment for Multi-dimensional FSD and Low Testosterone. Female Sexual Function Forum, 2000.
Slide 47-

Topical Alprostadil 1% alprostadil formulation (0.25 mL gel) Placed on glans penis, allowed to dry, then vaginal intercourse 36 healthy volunteer couples (16 treatment; 16 controls). All men had Erectile Dysfunction Results: No changes in vital signs in either partner Females: some noted improved clitoral/vaginal sensation Taintor, et al. Tolerance of Topical PGE1 Gel as a Topical Treatment for Erectile Dysfunction during Vaginal Intercourse, Female Sexual Function Forum, 2000.
Slide 48-

Alprostadil (PGE1) Pellets 2 women with vaginismus Given 1000 mcg alprostadil pellets to insert vaginally prior to sex Evaluated after for improvement in vaginal muscle spasm Results: both able to have intercourse without difficulty Benet, A. Intravaginal Alprostadil Pellets for Treatment of Vaginismus, Female Sexual Function Forum, 2000.
Slide 49-

Intranasal Apomorphine Acts centrally to facilitate erectile response 12 healthy women studied at 3 doses of Apomorphine Pharmacokinetics, nasal tolerance well tolerated thus far. Efficacy studies “at-home” currently underway Khan, et al. Evaluation of Nasal Apomorphine for FSD and Male ED as a function of dose, Female Sexual Function Forum, 2000.
Slide 50-

Neutraceutical Therapy Contents: Gingko balboa, Korean ginseng, L-arginine, calcium, iron, zinc and multi-vitamins 93 women (age 22-73 years); 46 treatment and 47 controls Subjects: 58 premenopausal women 16 perimenopausal women 19 post menopausal women
Slide 51-

Neutraceutical Therapy Results: PERI: 73% improvement in sexual desire 73% improvement in clitoral sensation 73% improvement in sexual satisfaction POST: 64% improvement in sexual satisfaction PRE: 71% increase in sexual desire 68% increase in sexual satisfaction Trant A. Clinical Study on a Nutritional Supplement for the enhancement of Female Sexual Function, Female Sexual Function Forum, 2000.
Slide 52-

L-arginine & Yohimbine 6 g arginine and 6mg yohimbine 23 post menopausal women with female sexual arousal disorder Physiological arousal measured by vaginal pulse amplitude Subjective arousal measured by questionnaire Erotic film shown after medication given Results: Increased VPA responses vs. placebo at 60 minutes but not 30 or 90 min. Drugs reach peak plasma levels at 40 min Meston CM. The effects of L-arginine and Yohimbine in Sexual Arousal in Postmenopausal Women with Female Sexual Arousal Disorder, Female Sexual Function Forum, 2000.
Slide 53-

Vacuum Clitoral Therapy Device Treatment designed to increase clitoral blood flow, enhance clitoral engorgement and improve arousal 32 subjects (20 with FSD and 12 without FSD) Results: Parameter FSD No FSD Greater sensation 90% 58% Increase lubrication 80% 33% Ability to achieve orgasm 55% 42% Increased sexual satisfaction 80% 25%
Slide 54-

Vacuum Clitoral Therapy Device Results: No side effects noted with use of device Study by same authors in 5 diabetic women with FSD Parameter Diabetic with FSD Greater sensation 4/5 (80%) Increase lubrication 3/5 (60%) Ability to achieve orgasm 3/5 (60%) Increased sexual satisfaction 4/5 (80%) Billups et al. Vacuum Induced Clitoral Engorgement for treatment of Female Sexual Dysfunction, female Sexual Function Forum, 2000.
Slide 55-

Conclusions An exciting area applicable to all physicians. Physicians need to learn through research and patient care about: Epidemiology Diagnosis Pathophysiology Treatment
Slide 56-

References Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther . 2000;26:191-208. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, et. al. Report of the International Consensus Development Conference on Female Sexual Dysfunction: Definitions and classifications. J Urol. 2000;163:888-893. Nicolosi A, Laumann EO, Glasser DB, Moreira ED, Pail A, and Gingell C. Sexual Behavior Sexual Dysfunctions Age 40: The Global Study of Sexual Attitudes and Behaviours. Urology. 2004;54(5): 991-997.
Slide 57-

References Laumann EO, Paik A, Rosen RC: Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA. Feb 10, 1999: Vol 281, No 6: 537-544. Peters KM, Killinger KA, Carrico DJ, Ibrahim IA, Diokno AC, and Graziottin A: Sexual Function and Sexual Distress in Women with Interstitial Cystitis: A Case Control Study. Urology. 2007; 70(3): 543-547. Zaslau S, Triggs J, Morgan L, Osborne J, Subit M, Riggs D: “Characterization of Female Sexual Dysfunction in Patients with Interstitial Cystitis.” Presented at the American Urological Society Meeting, Chicago, IL, April 27, 2003.
Slide 58-

References Zaslau S, Subit MJ, Mohseni HF, Riggs D, Jackson B, Kandzari S: “Sexual Dysfunction in Patients with Interstitial Cystitis.” Presented at the American Urogynecology Meeting, Hollywood, FL, September 12, 2003. Zaslau S, Subit MJ, Mohseni HF, Riggs D, Jackson B, Kandzari S. “Sexual Dysfunction in Patients with Interstitial Cystitis: Initial Analysis of Under 40 Cohort.” Presented at the Mid-Atlantic Section of the American Urological Society Meeting, Boca Raton, FL, October 26-29, 2003.